ClinicalTrials.gg
CompletedNCT05641558Updated Dec 7, 2022

Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis

A Phase 1/2 interventional study of 611 150mg and 611 300mg in Dermatitis, Atopic, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Completed at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-07.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Oct 2021, registered Nov 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
173rd of 190
24 · median 164
Started
2021
with 12 others
Phase 1/2
15 of 206
5 open now
Registered
55th of 206
by date
Lead sponsor
8 of 206
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 173rd largest by enrollment of the 190 interventional ones that give a count, is one of 13 that started in 2021, is one of 15 in phase 1/2, and was the 55th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

The primary objective of the study was to evaluate the safety and tolerability of 611 in chinese adults with moderate to severe atopic dermatitis.

Read the detailed description

The maximum study duration was 30 weeks per participants, including a screening period of up to 2 weeks, a 4-weeks single dose treatment period, and then a 16-weeks repeated dose treatment period, and an 8-week follow-up period.

03

Conditions studied

  • Dermatitis, Atopic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years or older who has AD (according to Williams Criteria) at the screening visit.
  • AD that had been present for at least 1 year before the baseline visit.
  • (BMI) was 19-32 kg/m\^2 (including boundary values), male subjects weighed ≥50.0kg, female subjects weighed ≥45.0kg.
  • Eczema Area and Severity Index (EASI) score greater than or equal to (>=) 16.
  • Investigator's Global Assessment (IGA) score >=3 (on the 0 to 4 IGA scale, in which 3 was moderate and 4 was severe).
  • Participants with >=10 percent (%) body surface area (BSA) of AD involvement.
  • Baseline Pruritus Numerical Rating Scale (NRS) average score for maximum itch intensity >=4.
  • Recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications or for whom topical treatments were otherwise medically inadvisable (e.g., because of important side effects or safety risks).
  • Have applied a stable dose of topical emollient (moisturizer) twice daily for at least the 7 consecutive days before the baseline visit.
  • Subject must be able to understand and complete the study related questionnaires and sign the written (ICF).

Exclusion criteria

Exclusion Criteria:

  • Presence of any one of the following lab abnormalities at screening: ≤ the lower limit of normal (LLN); White blood cell count below LLN; below LLN; Blood count below LLN; (ALT) or aspartate aminotransferase (AST) ≥ 2 times the (ULN); Total ≥ 1.5 × ULN; Serum creatinine (Cr) ≥ 1.5×ULN;
  • History of treatment with dupilumab, anti-interleukin (IL)-4 or IL13 agents.
  • Patients who have received any of the following treatments within 4 weeks before baseline: Treatment with /immunomodulating substances (e.g., systemic , cyclosporine, mycophenolate mofetil, interferon-gamma [IFN-γ], oral JAK inhibitors, compound glycyrrhizin, azathioprine, or methotrexate); Treatment with phototherapy (narrow band ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen + ultraviolet A [PUVA]), sunbed or any other light emitting device (LED) therapy;
  • Treatment with topical drugs such as corticosteroids, topical calcineurin inhibitors, phosphodiesterase (PDE) inhibitors, or Janus kinase (JAK) inhibitors within 1 weeks before baseline;
  • Treatment with systemic traditional Chinese medicine (TCM) within 4 weeks before baseline or treatment with topical TCM within 1 weeks before baseline;
  • Patients who have received any of the following biological agents: Treatment with cell depletion agents (e.g., rituximab) within 6 months before baseline. Treatment with other biological agents within 3 months before baseline or 5 drug half-lives (if known), whichever is longer;
  • Have undergone bleaching baths ≥ twice within 2 weeks before baseline;
  • Planned or anticipated use of any banned drugs or any prohibited therapeutic procedures during the study.
  • Have been vaccinated with live (attenuated) vaccine within 8 weeks before baseline or planned during the study period or within 12 months after the study;
  • History of to any biological agents. History of hypersensitivity to 611 or their .
  • Participants who had donated blood (≥200 ml) within 8 weeks before enrollment or had severe blood loss of ≥200 ml, received a blood transfusion within 8 weeks, or planned to donate blood during the course of the study.
  • Active chronic or acute infection requiring treatment with systemic anti-infective therapy within 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit.
  • Known or suspected history of immunosuppression, including history of invasive opportunistic infections (e.g., tuberculosis [TB], histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis).
  • Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
  • History of alcohol within 6 months before baseline.
  • Smoking more than 5 cigarettes per day within 3 months before the screening visit, or unable to stop using any tobacco products during the trial;
  • History of drug abuse or urine drug screening was positive.
  • surface Antigen (HBsAg)-positive, or Hepatitis B core Antibody (HbcAb) was positive and Hepatitis B surface Antibody (HBsAb) was negative, or Virus Antibodie (HCV Ab)-positive, Antibody (HIV Ab) positive;
  • Presence of skin comorbidities that may interfere with study assessments.
  • History of within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non- squamous or basal cell carcinoma of the skin.
  • History of parasitic infections within 6 months before baseline.
  • Any medical condition that, in the opinion of the investigator, is serious or unstable and may affect the subject's safety and/or prevent the subject from completing the study.
  • Any other medical or psychological condition that was judged by the investigator to be ineligible for enrollment.
  • Planned or anticipated major surgical procedure during the patient's participation in this study.
  • Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period. Women/men unwilling or unable to use highly effective throughout the study period until at least 6 months after the last dose of study drug, and Women of (WOCBP) who had a positive pregnancy test and/or were unwilling or unable to undergo a pregnancy test
  • Other conditions were deemed by the investigator to be inappropriate for trial participation.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    611 dose 1 plus placebo

    One subcutaneous injections of 611 150 mg on Day 1, followed by a 4-week observation period. Two subcutaneous injections of 611 150 mg (for a total of 300 mg) as a loading dose on Week 0 Day 29, followed by one 150 mg injection quaque week (QW) from Week 1 to Week 15 (15 cycles).

    Drug: 611 150mg · Other: Placebo

  • Experimental
    611 dose 2 plus placebo

    Two subcutaneous injections of 611 150 mg (for a total of 300 mg) on Day 1, followed by a 4-week observation period. Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on Week 0 Day 29, followed by one 300 mg injection quaque 2 week (Q2W) from Week 1 to Week 15 (8 cycles).

    Drug: 611 300mg · Other: Placebo

  • Experimental
    611 dose 3 plus placebo

    Four subcutaneous injections of 611 150 mg (for a total of 600 mg) on Day 1, followed by a 4-week observation period. Four subcutaneous injections of 611 150 mg (for a total of 600 mg) as a loading dose on Week 0 Day 29, followed by one 300 mg injection QW from Week 1 to Week 15 (15 cycles).

    Drug: 611 600mg · Other: Placebo

Interventions

  • subcutaneous injection, 150 mg (single dose treatment period) + 300mg (loading dose, week 0) + 150mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)

  • subcutaneous injection, 300 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 1 to Week 15, 8 cycles)

  • subcutaneous injection, 600 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)

  • OtherPlacebo

    During the study, placebos shall be filled timely according to the administration of the test drug to ensure the consistency of the times of administration in each group, so as to maintain the blind state.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs), measurement of vital signs,physical examination,electrocardiogram and laboratory tests at each visit.

    The incidence and severity of treatment emergent adverse event (TEAE), including Serious Adverse Event (SAE), as well as clinical symptoms, and any abnormalities of vital signs, physical examinations,electrocardiogram,laboratory tests and, etc.

    Time frame: Up to 24 Weeks (Day 197).

Secondary outcomes

  1. Maximum Concentration (Cmax).

    Maximum Observed Serum Concentration (Cmax) of 611

    Time frame: Baseline to Week 24 (Day 197).

  2. Minimum concentration (Cmin).

    Minimum concentration (Cmin) of 611.

    Time frame: Baseline to Week 24 (Day 197).

  3. Time to Reach the Maximum Concentration (Tmax).

    Time to Reach the Maximum Serum Concentration (Tmax) of 611.

    Time frame: Baseline to Week 24 (Day 197).

  4. Area under the serum concentration-time curve from 0 to the time of the last quantifiable concentration (AUC0-last).

    Area under the serum concentration-time curve from 0 to the time of the last quantifiable concentration (AUC0-last) of 611.

    Time frame: Baseline to Week 24 (Day 197).

  5. AUC to the end of the dosing period (AUC0-tau)

    AUC to the end of the dosing period (AUC0-tau) of 611.

    Time frame: Baseline to Week 24 (Day 197).

  6. Clearance rate (CL/F).

    Clearance rate (CL/F) of 611.

    Time frame: Baseline to Week 24 (Day 197).

  7. Percentage of Participants With Anti-drug Antibodies and Neutralizing Antibodies.

    Immunogenicity assessment will be based on Anti-drug Antibodies (ADAs) response and development of Neutralizing Antibodies (NABs). Percentage is calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-drug antibodies / number of evaluable participants \* 100%.

    Time frame: Baseline to Week 24 (Day 197).

  8. Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Improvement From Baseline of Greater Than or Equal to (>=) 2 Points at Week 8(Day 85), Week 12(Day 113), Week 16(Day 141).

    The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.

    Time frame: Baseline , Week 8(Day 85), Week 12(Day 113), Week 16(Day 141).

  9. Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Improvement in Score From Baseline) at Week 8(Day 85), Week 12(Day 113), Week 16(Day 141).

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

    Time frame: Baseline , Week 8(Day 85), Week 12(Day 113), Week 16(Day 141).

  10. Percentage Change in EASI Score

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

    Time frame: Baseline , Week 8(Day 85), Week 12(Day 113), Week 16(Day 141).

  11. Percentage Change in Percent Body Surface Area (BSA) of AD Involvement.

    BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections.

    Time frame: Baseline , Week 8(Day 85), Week 12(Day 113), Week 16(Day 141).

  12. Number of Participants Who Achieved >=4 Points With Improvement From Baseline in Weekly Average of Pruritus Numerical Rating Scale (NRS) Score at Week 8(Day 85), Week 12(Day 113), Week 16(Day 141).

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

    Time frame: Baseline , Week 8(Day 85), Week 12(Day 113), Week 16(Day 141).

  13. Change in serum concentrations of Thymus and activation regulated chemokine (TARC)

    Change in serum concentrations of TARC

    Time frame: Baseline to Week 24 (Day 197).

  14. Change in serum concentrations of immunoglobulin E (IgE)

    Change in serum concentrations of IgE.

    Time frame: Baseline to Week 24 (Day 197).

  15. Change in whole blood eosinophil counts

    Change in whole blood eosinophil counts.

    Time frame: Baseline to Week 24 (Day 197).

  16. Change in serum concentrations of lactate dehydrogenase (LDH)

    Change in serum concentrations of lactate dehydrogenase (LDH).

    Time frame: Baseline to Week 24 (Day 197).

07

Study locations

5 sites
  • The First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui 241001, China
  • Peking University Shougang Hospital
    Beijing, Beijing 100144, China
  • Nanyang First People's Hospital
    Nanyang, Henan 473010, China
  • Dermatology Hospital of Jiangxi Province
    Nanchang, Jiangxi 330001, China
  • The First of Hospital China Medical University
    Shenyang, Liaoning 110001, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Oct 2022, 12 months.

Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 12 months is below that.

Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2022
First posted
Dec 7, 2022
StartActual
Oct 18, 2021
Primary completionActual
Oct 21, 2022
CompletionActual
Oct 21, 2022
Last update
Dec 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05641558
Responsible party
Sponsor
First posted
Dec 7, 2022
Start date
Oct 18, 2021
Primary completion
Oct 21, 2022
Completion
Oct 21, 2022
Last update
Dec 7, 2022

Study contacts

Xinghua Gao, MD
principal investigator · The First of Hospital China Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camtarkibart

Start the discussion